HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC anticaries biological testing plan requested by FDA in petition response.

This article was originally published in The Rose Sheet

Executive Summary

OTC ANTICARIES BIOLOGICAL TESTING SCHEDULE REQUIRED BY FDA before it will make a final decision on extending the effective date of the biological testing requirements in the OTC anticaries final monograph by 12 months to Oct. 7, 1997. The petition requested the extension in order to provide Nonprescription Drug Manufacturers Association and Cosmetic, Toiletry and Fragrance Association members sufficient time to comply with the requirements and to provide reference standards to the U.S. Pharmacopoeia for formulas included in the final monograph ("The Rose Sheet" April 7, p. 15). FDA informed NDMA of its decision in a May 24 letter, which responds to an April 17 citizen petition submitted on behalf of an NDMA/CTFA joint task force.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002915

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel